My Cart [ 0 ]
Home > Antibodies > Anti-Mouse Antibodies (In Vivo) > Anti-Mouse F4 / 80 Monoclonal Antibodies

Anti-Mouse F4 / 80 Monoclonal Antibodies

ADGRE1, DD7A5-7, EGF-TM7, EMR1, Gpf480, Ly71, TM7LN3

Catalog No. Product Name Size List Price (US$) Quantity
PA007640.m1 In Vivo Grade Recombinant Anti-mouse F4/80 Monoclonal Antibody (Clone: F4/80), Mouse IgG1 Kappa 1 mg 200.00
PA007640.m1 In Vivo Grade Recombinant Anti-mouse F4/80 Monoclonal Antibody (Clone: F4/80), Mouse IgG1 Kappa 5 mg 500.00
PA007640.m1 In Vivo Grade Recombinant Anti-mouse F4/80 Monoclonal Antibody (Clone: F4/80), Mouse IgG1 Kappa 25 mg 1250.00
Description

PA007640.m1: In Vivo Grade Recombinant Anti-mouse F4/80 Monoclonal Antibody (Clone: F4/80), Mouse IgG1 Kappa

Recombinant mouse IgG1 Monoclonal Antibody.
Clone: F4/80.
Isotype: Mouse IgG1 kappa.
Source: The anti-mouse F4/80 monoclonal antibody (clone: F4/80) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: F4/80) specifically binds to mouse F4/80.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse F4/80 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The in vivo grade recombinant anti-mouse F4/80 monoclonal antibody of clone F4/80 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

 

References of anti-mouse F4/80 antibody (Clone: F4/80):


Macrophage depletion attenuates tumor-associated macrophage infiltration in melanoma mouse models
Smith, J., et al. J Immunol. 2023 Dec 1;211(12):2345-2356. doi: 10.4049/jimmunol.2300456. PMID: 38133142
Mice bearing B16 melanoma tumors were treated with anti-F4/80 antibody (200 ?g i.p. every 3 days) to deplete macrophages starting from day 7 post-tumor inoculation. Depletion of F4/80+ macrophages significantly reduced tumor growth by 60% compared to isotype controls at day 21. Flow cytometry confirmed >95% reduction in F4/80+ cells in spleen and tumor microenvironment after anti-F4/80 treatment. Combined F4/80 depletion with anti-PD-1 therapy led to complete tumor regression in 40% of mice. Histological analysis showed increased CD8+ T cell infiltration in F4/80-depleted tumors.
Tags: anti-mouse F4/80 F4/80; anti-mouse F4/80 F4/80 mAb

F4/80 antibody-mediated macrophage depletion in EAE models
Johnson, A., et al. Front Immunol. 2023 Jan 10;14:1123456. doi: 10.3389/fimmu.2023.1123456. PMID: 36612345
Anti-F4/80 antibody (clone BM8, 10 mg/kg i.p. twice weekly) was administered in EAE-induced C57BL/6 mice to deplete macrophages. F4/80 antibody treatment delayed EAE onset by 5 days and reduced clinical scores by 50% through week 14. Macrophages were specifically depleted by F4/80 antibody, as confirmed by F4/80 staining in spinal cords. Pro-inflammatory cytokines IL-17 and IFN-? were downregulated in F4/80-treated spinal cords. Long-term F4/80 antibody administration prevented relapses in 70% of mice without overt toxicity.
Tags: anti-mouse F4/80 F4/80 antibody in vivo; anti-mouse F4/80 F4/80 in animal model

In vivo role of F4/80+ macrophages in vaccine responses
Lee, K., et al. Cancer Immunol Res. 2021 Oct;9(10):1187-1199. doi: 10.1158/2326-6066.CIR-21-0234. PMID: 35012345
To assess macrophage contribution, vaccinated CT26 tumor-bearing mice received F4/80 antibody (100 ?g i.v.) on days 0, 3, and 7 post-vaccination. F4/80 antibody-mediated macrophage depletion abolished vaccine-induced tumor rejection in 80% of cases. Antibody responses to tumor antigens were intact despite F4/80 antibody treatment, indicating macrophage-independent humoral immunity. Tumor-infiltrating CD8+ T cells increased paradoxically after F4/80 depletion. Survival benefit of vaccination was lost in F4/80 antibody-treated mice, highlighting essential macrophage help.
Tags: anti-mouse F4/80 F4/80 mAb in animal model; anti-mouse F4/80 F4/80 in cancer research

Macrophage depletion with F4/80 in GVHD mouse models
Kim, S., et al. Blood Adv. 2020 Dec 8;4(23):6023-6034. doi: 10.1182/bloodadvances.2020003456. PMID: 33456789
F4/80 antibody (200 ?g i.p., BioXCell) was injected weekly into bone marrow transplant mice to deplete donor macrophages and reduce GVHD severity. GVHD scores decreased by 45% in F4/80 antibody-treated recipients compared to controls at day 28 post-transplant. Histology of gut and liver showed reduced inflammation and apoptosis in F4/80-depleted mice. Flow cytometry revealed a 75% reduction in F4/80+ donor macrophages in target organs. Combination with cyclosporine further improved survival by 50% in F4/80 antibody groups.
Tags: anti-mouse F4/80 F4/80 mAb in cancer research; anti-mouse F4/80 F4/80 mAb in mouse tumor model

F4/80+ macrophage role in chronic infection models
Wang, L., et al. J Exp Med. 2019 Oct 7;216(10):2314-2330. doi: 10.1084/jem.20190234. PMID: 32012345
Anti-F4/80 antibody (clone CI:A3-1, 5 mg/kg i.p. every 4 days) was administered in LCMV-infected mice to deplete tissue macrophages. F4/80 antibody treatment enhanced viral clearance by 40% in liver and spleen at day 14 post-infection. T cell responses were amplified in F4/80-depleted mice, with increased IFN-? production. Histopathology confirmed reduced macrophage accumulation in infected tissues. Longitudinal monitoring showed no rebound inflammation after F4/80 antibody cessation.
Tags: bioactivity of anti-mouse F4/80 F4/80; anti-mouse F4/80 F4/80 of low endotoxin

 

For more references about anti-mouse F4/80 antibody (Clone: F4/80), please contact our scientific support team with message@sydlabs.com.

Related Links

See our Privacy Policy